# Bactobio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bactobio

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.bacto.bio
- Latest round: Seed (Jul 1, 2020)
- Investors on record: 1

## About

Bactobio Ltd is a UK-based company dedicated to the discovery and development of innovative antimicrobial solutions sourced from previously unculturable microbes, catering to the healthcare and agricultural sectors.Bactobio Ltd operates in the UK, specifically in London, focusing on the development of novel antimicrobial solutions. The company was founded in 2020 by Andreas Harris and Daniel Hansen. In December 2022, Bactobio secured GBP 6 million in funding led by Bridford Investments Ltd., aimed at accelerating its discovery pipeline. The company has completed 8 deals to date, with a current valuation of GBP 57.934 mn. Daniel Hansen serves as the CEO of the company.Bactobio specializes in the discovery and development of novel antimicrobial solutions derived from previously unculturable microbes. The company leverages advanced genomic techniques, machine learning, and bioengineering to unlock the potential of these microbes, which have evolved to produce effective, specific, and biodegradable chemistries. Their core offerings are primarily targeted at healthcare and agricultural sectors, addressing the critical need for safer antimicrobial agents and plant protectants. Bactobio's solutions aim to mitigate the impacts of pathogens and pollutants, contributing to environmental sustainability and public health. The company serves a diverse clientele, including healthcare providers, agricultural firms, and researchers, and operates in key markets across Europe, North America, and Asia.Bactobio generates revenue through strategic partnerships and collaborations with healthcare and agricultural organizations. These transactions typically involve the licensing of their proprietary microbial technologies and the co-development of tailored solutions that meet specific client needs. The company’s flagship products may be integrated into broader healthcare protocols or agricultural practices, enhancing the efficacy of existing treatments and reducing dependency on traditional chemical agents. Pricing structures vary based on the scope of collaboration and the nature of the services rendered, with arrangements potentially involving milestone payments, royalties, or subscription models for ongoing access to their innovative microbial solutions.In December 2022, Bridford Group led a GBP 6 million venture funding for Bactobio Ltd, which will be utilized to accelerate the company's discovery pipeline and enable the characterization of the next generation of antimicrobial solutions. Bactobio is focused on expanding its product offerings and plans to introduce new antimicrobial solutions targeted for launch in the coming years. The company is also exploring opportunities to enter new geographic markets, particularly in Asia and North America, by 2024.

## Funding rounds

- Seed, Jul 1, 2020 — Pioneer Fund

## Investors

- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed